Verastem, Inc.
avutometinib capsules; defactinib tablets
adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant-type (mt) recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Resolved
188days ago
Approval decision · Dec 31, 2025
What's at stake
A final FDA approval decision on avutometinib capsules; defactinib tablets for adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant-type (mt) recurrent Low-Grade Serous Ovarian Cancer (LGSOC) is expected Dec 31, 2025.
Primary source
· SEC 8-K
verified 16h ago
“May 8 FDA approval through December 2025.”